AstraZeneca’s Q4 operating performance came in ahead of our expectations, with revenue growing at 2% at CER to $6.4bn and attributable net income coming in at $808m (from a loss of $321m in Q4 14). NB all revenue growth numbers are at CER unless specified otherwise. The strong dollar, however, pushed the revenue growth to a decline of 5%. For the full year, while the revenue of $24.7bn was just shy of our $24.9bn estimate (and ahead of management's guidance), attributable net profit out
02 Mar 2016
Strong Q4 but heading towards a challenging 2016
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong Q4 but heading towards a challenging 2016
AstraZeneca PLC (AZN:LON) | 10,689 -6841 (-0.6%) | Mkt Cap: 165,702m
- Published:
02 Mar 2016 -
Author:
Kamla Singh -
Pages:
3
AstraZeneca’s Q4 operating performance came in ahead of our expectations, with revenue growing at 2% at CER to $6.4bn and attributable net income coming in at $808m (from a loss of $321m in Q4 14). NB all revenue growth numbers are at CER unless specified otherwise. The strong dollar, however, pushed the revenue growth to a decline of 5%. For the full year, while the revenue of $24.7bn was just shy of our $24.9bn estimate (and ahead of management's guidance), attributable net profit out